Selective CDK4/6 inhibitors (CDK4/6i), such as palbociclib, abemaciclib and ribociclib have received FDA approval for the treatment of estrogen receptor-positive (ER + )/HER2-negative breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.